Screening and prevention of ovarian cancer
2024/02/14 by Michail Sideris, Usha Menon, Ranjit Manchanda · 105 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer #Cancer-related molecular mechanisms research #Context (archaeology) #Endometrial and Cervical Cancer Treatments #Gynecology #Hormone replacement therapy (female-to-male) #Hysterectomy #Internal medicine #Medicine #Menopause #Obstetrics #Oncology #Oophorectomy #Ovarian cancer #Ovarian cancer diagnosis and treatment #Population #Pregnancy #Salpingectomy #Surgery
paper · pdf · doi:10.5694/mja2.52227
published in The Medical Journal of Australia 220(5), 264-274 (Wiley)
openalex publication_date 2024/02/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Abstract
Ovarian cancer remains the most lethal gynaecological malignancy with 314 000 cases and 207 000 deaths annually worldwide. Ovarian cancer cases and deaths are predicted to increase in Australia by 42% and 55% respectively by 2040. Earlier detection and significant downstaging of ovarian cancer have been demonstrated with multimodal screening in the largest randomised controlled trial of ovarian cancer screening in women at average population risk. However, none of the randomised trials have demonstrated a mortality benefit. Therefore, ovarian cancer screening is not currently recommended in women at average population risk. More frequent surveillance for ovarian cancer every three to four months in women at high risk has shown good performance characteristics and significant downstaging, but there is no available information on a survival benefit. Population testing offers an emerging novel strategy to identify women at high risk who can benefit from ovarian cancer prevention. Novel multicancer early detection biomarker, longitudinal multiple marker strategies, and new biomarkers are being investigated and evaluated for ovarian cancer screening. Risk-reducing salpingo-oophorectomy (RRSO) decreases ovarian cancer incidence and mortality and is recommended for women at over a 4-5% lifetime risk of ovarian cancer. Pre-menopausal women without contraindications to hormone replacement therapy (HRT) undergoing RRSO should be offered HRT until 51 years of age to minimise the detrimental consequences of premature menopause. Currently risk-reducing early salpingectomy and delayed oophorectomy (RRESDO) should only be offered to women at increased risk of ovarian cancer within the context of a research trial. Pre-menopausal early salpingectomy is associated with fewer menopausal symptoms and better sexual function than bilateral salpingo-oophorectomy. A Sectioning and Extensively Examining the Fimbria (SEE-FIM) protocol should be used for histopathological assessment in women at high risk of ovarian cancer who are undergoing surgical prevention. Opportunistic salpingectomy may be offered at routine gynaecological surgery to all women who have completed their family. Long term prospective opportunistic salpingectomy studies are needed to determine the effect size of ovarian cancer risk reduction and the impact on menopause.
Citations
Cited by
- From desert flora to cancer therapy: systematic exploration of multi-pathway mechanisms using network pharmacology and molecular modeling approaches. [europepmc]
- Global burden of gynaecological cancers in 2022 and projections to 2050. [europepmc]
- Ten Hypermethylated lncRNA Genes Are Specifically Involved in the Initiation, Progression, and Lymphatic and Peritoneal Metastasis of Epithelial Ovarian Cancer. [europepmc]
- Indirubin induces apoptosis in ovarian cancer cells via the mitochondrial pathway. [europepmc]
- Forced Vasohibin-1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity. [europepmc]
- Endothelial Dysfunction Markers in Ovarian Cancer: VTE Risk and Tumour Prognostic Outcomes. [europepmc]
- Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS. [europepmc]
- Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer. [europepmc]
- Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer. [europepmc]
- Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study. [europepmc]
- Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer. [europepmc]
- Carbon Nanotubes in the Diagnosis and Treatment of Ovarian Cancer. [europepmc]
- Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-to-Screen Cancers. [europepmc]
- Inherited Susceptibility to Cancer: Past, Present and Future. [europepmc]
- Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics. [europepmc]
- Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021. [europepmc]
- Role of long non-coding RNA-mRNA interactions in resveratrol-mediated inhibition of ovarian cancer cell proliferation. [europepmc]
- Early-fusion hybrid CNN-transformer models for multiclass ovarian tumor ultrasound classification. [europepmc]
- Global burden of ovarian and uterine cancers attributable to high body-mass index in 204 countries and territories, 1990-2021. [europepmc]
- Cellular cAMP Content and Mitochondrial Profile Define Different Subtypes of Ovarian Cancer Cells. [europepmc]
- Diabetes mellitus and the risk of ovarian cancer: an updated systematic review and meta-analysis of cohort and case-control studies. [europepmc]
- Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review. [europepmc]
- Redox-Amino Acid Metabolic Crosstalk in Ovarian Cancer Stem Cells: Integrating Metabolic Reprogramming, Signaling, and the Tumor Microenvironment. [europepmc]
- Evaluating the information quality and reliability of ovarian cancer educational content on TikTok and Bilibili: a cross-sectional study. [europepmc]
- Hereditary Endometrial Cancer: Lynch Syndrome, Mismatch Repair Deficiency, and Emerging Genetic Predispositions-A Comprehensive Review with Clinical and Laboratory Guidelines. [europepmc]
Related